Get the Stockscreener App
12.54
4.28%
0.515
Pre-market:
12.40
-0.135
-1.08%
Mink Therapeutics Inc stock is traded at $12.54, with a volume of 27,530.
It is up +4.28% in the last 24 hours and up +16.93% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
See More
Previous Close:
$12.02
Open:
$12.29
24h Volume:
27,530
Relative Volume:
0.51
Market Cap:
$62.45M
Revenue:
-
Net Income/Loss:
$-12.49M
P/E Ratio:
-4.2279
EPS:
-2.9648
Net Cash Flow:
$-5.93M
1W Performance:
+10.54%
1M Performance:
+16.93%
6M Performance:
+2.91%
1Y Performance:
+72.90%
1-Day Range:
$11.96
$12.72
1-Week Range:
$11.34
$12.72
52-Week Range:
$6.80
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
12.54 | 62.45M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Number of shareholders of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Number of shareholders of MiNK Therapeutics, Inc. – FWB:6Q40 - TradingView
INKT Technical Analysis & Stock Price Forecast - Intellectia AI
MiNK Therapeutics (INKT) Rallies 1.19% as Support Holds Firm Near $11.72IV Contraction - newsline.com
INKT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor SentimentProfit Warning Alert - newsline.com
Discipline and Rules-Based Execution in INKT Response - Stock Traders Daily
Number of shareholders of MiNK Therapeutics, Inc. – LS:A40ZAV - TradingView
INKT Q1 2026 Earnings: EPS Beat on Narrower Loss, But Stock Drops 5%Quarterly Earnings Report - newsline.com
MiNK Therapeutics (INKT) Pulls Back Sharply: Support Test LoomsStrangle Setup - newsline.com
Insider Sell: Barbara Ryan Sells 1,500 Shares of MiNK Therapeuti - GuruFocus
MiNK Therapeutics Q1 earnings call highlights - MSN
Mink Therapeutics director Barbara Ryan sells $19,141 in stock By Investing.com - Investing.com Canada
Mink Therapeutics director Barbara Ryan sells $19,141 in stock - Investing.com India
Director at MiNK Therapeutics (NASDAQ: INKT) sells 1,500 shares - Stock Titan
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - The Manila Times
How to join MiNK Therapeutics’ June 17 virtual shareholder meeting - Stock Titan
MiNK Therapeutics (INKT) Holds Near $12.0 as Trading Volume Remains ModestIchimoku Kumo Break - newsline.com
MiNK Therapeutics (NASDAQ: INKT) director granted RSU-based stock awards for board service - Stock Titan
MiNK Therapeutics (INKT) director granted stock units instead of cash retainers - Stock Titan
MiNK Therapeutics (INKT) director receives RSUs for board pay - Stock Titan
Director at MiNK Therapeutics (NASDAQ: INKT) receives RSU board compensation - Stock Titan
MiNK Therapeutics (NASDAQ: INKT) director receives RSU grants instead of cash retainers - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
Behavioral Patterns of INKT and Institutional Flows - Stock Traders Daily
INKT Begins Phase 2 Trial for Severe Acute Lung Injury Treatment - GuruFocus
INKT Q1 2026 Earnings: Better-Than-Expected Loss Drives 15.9% Stock RallyEPS Growth Report - thelegaladvocate.com
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - Investing News Network
Mink Therapeutics Doses First Patient in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness - marketscreener.com
Why is Mink Therapeutics stock surging today? By Investing.com - Investing.com Canada
MiNK Therapeutics doses first patient in lung injury trial - Investing.com UK
MiNK Therapeutics doses first patient in lung injury trial By Investing.com - Investing.com Nigeria
New cell therapy tested in Ukraine ICU for severe acute lung injury - Stock Titan
MiNK Therapeutics Q1 2026 Earnings: Narrowed Loss Exceeds Expectations Amid Clinical ProgressEarnings Deceleration Risk - The Legal Advocate
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - Investing News Network
MiNK Therapeutics Reports Promising Results from Phase 2 Trial of agenT-797 and N-803 Combination Therapy for Coccidioides immitis Infection - Quiver Quantitative
MiNK Therapeutics Reports New Data on agenT-797, an - GlobeNewswire
MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026 - MSN
MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co. - Moomoo
(INKT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate - Yahoo Finance
User | bigspringherald.comMiNK Therapeutics, Inc.Common Stock (Nasdaq:INKT) Stock Quote - FinancialContent
About Us - FinancialContent
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway - The Globe and Mail
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics starts phase 2 trial for lung injury therapy - Investing.com UK
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q1 2026 Earnings Conference - Moomoo
Mink Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):